Tonlamarsen for High Blood Pressure

(KARDINAL-ASH Trial)

Recruiting at 3 trial locations

Overseen By Kardigan Clinical Study Information Team

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Kardigan, Inc.

Disqualifiers: Secondary hypertension, Malignancy, Liver disease, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 6

Duration: 12 weeks

100 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently discharged from the hospital, after treatment for acute severe hypertension.

Are You a Good Fit for This Trial?

Inclusion Criteria

* Recently discharged from the hospital to home within the past 3 days during which evaluation and/or treatment of acute severe hypertension (documented systolic blood pressure \>180 mmHg and/or diastolic \>110 mmHg) occurred, as measured by a healthcare provider within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization

* At Screening and Randomization visit, average systolic blood pressure \> 145 mmHg

I have diagnosed heart or kidney conditions.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Treatment

Participants receive monthly doses of tonlamarsen or placebo for approximately 3 months

12 weeks

3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

8 weeks

2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Tonlamarsen

How Is the Trial Designed?

Group I: Tonlamarsen Experimental Treatment 1 Intervention

3 doses active drug will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks)

Group II: Placebo Placebo Group 1 Intervention

3 doses of placebo will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks)

Who Is Running the Clinical Trial?

Kardigan, Inc.

Lead Sponsor

Trials

1

Recruited

700+